+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilars: EU5 Access & Reimbursement

  • ID: 4705737
  • Report
  • May 2018
  • Region: Global
  • 53 pages
  • Decision Resources Group
1 of 3

FEATURED COMPANIES

  • Amgen
  • Cell Pharm
  • Celltrion
  • Hexal
  • Hospira
  • Medice Arzneimittel
  • MORE
This EU5 Biosimilars Access & Reimbursement report provides brand-level insight regarding the impact of payer policy on physician prescribing behavior in the EU5 Biosimilars market so you can optimize your market access strategy and determine how to best position your biosimilar to specific stakeholders.

This report includes specific detail on the Biosimilars market access trends in EU5, insight on how to maximize opportunity and limit barriers, analysis of key reimbursement decision-makers and the criteria they use, review of market access strategies used by competitors and highlights of where they succeeded or stumbled, detailed analysis of physician and payer perceptions based on physician surveys in-depth interviews with payers, and much more. This report is most relevant for professionals in market research, business intelligence, market access, brand teams, launch planning teams, business development & licensing. This report was published in May 2018.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen
  • Cell Pharm
  • Celltrion
  • Hexal
  • Hospira
  • Medice Arzneimittel
  • MORE
1. Key Findings
2. Regulations and Guidance
3. EMA overarching biosimilars guidance
4. Automatic substitution
5. Pricing
6. Reimbursement
7. Strategies to drive uptake
8. Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer
  • Amgen
  • Hexal
  • Teva
  • Celltrion
  • Cell Pharm
  • Mundipharma
  • Ratiopharm
  • Medice Arzneimittel
  • Sandoz
  • Hospira
Note: Product cover images may vary from those shown
Adroll
adroll